# Vitamin D and Type 2 Diabetes - Treat-To-Target

Study · id `cardio:ct-nct07448974` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07448974](<https://clinicaltrials.gov/study/NCT07448974>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07448974

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07448974. Randomized; quadruple masking; primary purpose other. Start 2026-08-04 (actual); primary completion 2030-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose other
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07448974, source copy `cardio:ctgov-nct07448974-2026-08-18`, retrieved 2026-10-26)
- Started: 2026-08-04 (actual) (ClinicalTrials.gov record NCT07448974, source copy `cardio:ctgov-nct07448974-2026-08-18`, retrieved 2026-10-26)
- Primary completion: 2030-03 (anticipated) (ClinicalTrials.gov record NCT07448974, source copy `cardio:ctgov-nct07448974-2026-08-18`, retrieved 2026-10-26)
- Completion: 2031-03 (anticipated) (ClinicalTrials.gov record NCT07448974, source copy `cardio:ctgov-nct07448974-2026-08-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07448974, source copy `cardio:ctgov-nct07448974-2026-08-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07448974-2026-08-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vitamin D and Type 2 Diabetes - Treat-To-Target
- Acronym: D2d-TTT
- Condition: Prediabetes
- Condition: Type 2 Diabetes (T2DM)
- Intervention (Drug): Vitamin D (Cholecalciferol )
- Intervention (Drug): Placebo
- Lead sponsor: Tufts Medical Center
- Lead sponsor class: OTHER
- Collaborator: Abiogen Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Tufts Medical Center (`cardio:org-tufts-medical-center`)

## Provenance

Content hash: 2a0b1aea63ccb028036f53b95077f9864eb51eb9a8c94bd2f127d54a09a6a5bd
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
